However, the combination of ARBs with ACE inhibitors is not recommended, because there is less evidence of a benefit from this combination on cardiovascular disease or DN compared to monotherapy, in addition to the increased incidence of side effects such as hyperkalemia [154]. The gene discussed is ACE; the disease is cardiovascular disorder.